Loading, Please Wait...
WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it will present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 at 1:30 p.m. Eastern Standard Time at The Boston Marriot Copley Place in Boston.
The presentation will be given by Apellis founder and chief executive officer Cedric Francois, MD, PhD, and will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the Company’s website at http://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. For additional information about Apellis and APL-2, please visit http://www.apellis.com.
Media Contact: Tully Nicholas email@example.com 617.482.0042 (office) 860.490.0218 (mobile) Investor Contact: Alex Kane firstname.lastname@example.org 212.301.7218 (office) 929.400.2691 (mobile)